血管内大B细胞淋巴瘤PD-L1表达与临床病理特征的相关性研究
本研究回顾性分析11例血管内大B细胞淋巴瘤(IVLBCL)病例,采用CD20、CD3、CD5、PD-L1免疫组化染色,按2017 WHO标准分为经典型和噬血细胞综合征(HPS)变异型。结果显示4/9例可评估病例(44.4%)PD-L1阳性,经典型和HPS变异型均可表达,且与CD5表达无关,提示部分IVLBCL患者可能受益于靶向免疫治疗。
要点
- 44.4%(4/9)可评估IVLBCL病例PD-L1阳性。
- 经典型和HPS变异型均可表达PD-L1。
- PD-L1表达与CD5表达无关。
核心结论
- 部分血管内大B细胞淋巴瘤表达PD-L1,经典型和HPS变异型均可表达,且与CD5表达无关。
- 检测PD-L1可能识别可从靶向免疫治疗中获益的IVLBCL患者。
研究设计与样本
- 回顾性分析美国国立癌症研究所病理实验室存档的11例IVLBCL病例。
- 采用CD20、CD3、CD5、PD-L1免疫组化染色,按2017 WHO标准分为经典型和HPS变异型。
主要发现
- 3例(27.3%)为HPS变异型,8例(72.7%)为经典型。
- 5/11例(45.5%)CD5阳性,其中HPS变异型2/3例(66%),经典型3/8例(37.5%)。
- 4/9例可评估病例(44.4%)PD-L1阳性,其中3例为经典型。
- 仅1例CD5阳性病例PD-L1阳性,为经典型。
临床怎么用
- 对IVLBCL病例可考虑检测PD-L1表达,以筛选潜在免疫治疗获益者。
局限性
- 样本量小(11例),可评估PD-L1的病例仅9例,数据有限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Intravascular large B cell lymphoma (IVLBCL) is a rare, aggressive, extranodal large B cell lymphoma characterised by growth of tumour cells within the lumen of vessels, particularly capillaries. Programmed cell death ligand 1 (PD-L1) is a cell surface glycoprotein that interacts with programmed death 1 (PD-1) on the T cell surface, leading to modulation of the immune response. PD-L1 is a targetable immune check-point molecule that is expressed on neoplastic cells in various cancers, including a subset of lymphomas. We correlated the expression of PD-L1 with clinical and pathological findings in this rare disease. Eleven cases of IVLBCL were identified in the archives of Laboratory of Pathology at the National Cancer Institute, NIH. A panel of immunostains (CD20, CD3, CD5, PD-L1) was performed. The cases were classified as the classic form or the variant associated with haemophagocytic syndrome (HPS) based on published 2017 WHO criteria. Three cases (27.3%) were HPS variant and eight cases (72.7%) were the classic form. Five (45.5%) of 11 cases were CD5-positive; two of three (66%) were HPS variants and three of eight (37.5%) were classic form. Overall, four of nine evaluable cases (44.4%) were positive for PD-L1, three of which were classic. Only one CD5-positive case was PD-L1-positive, a classic variant. In summary, a subset of IVLBCL express PD-L1. Although limited, these data suggest that PD-L1 is expressed in both the so-called classic form as well as the HPS variant. PD-L1 is expressed irrespective of CD5 expression. Finally, detection of PD-L1 expression in a subset of IVLBCL lymphoma cases may identify patients who might benefit from targeted immunotherapy.
引用
- Gupta GK, Jaffe ES, Pittaluga S, et al. A study of PD-L1 expression in intravascular large B cell lymphoma: correlation with clinical and pathological features. Histopathology. 2019. PMID: 30938862. doi:10.1111/his.13870
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。